AbbVie (ABBV) Tops Q3 EPS by 10c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.33, $0.10 better than the analyst estimate of $3.23. Revenue for the quarter came in at $14.34 billion versus the consensus estimate of $14.35 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.63-$12.67, versus the consensus of $12.59.

• AbbVie is raising its GAAP diluted EPS guidance for the full-year 2021 from $6.04 to $6.14 to $6.29 to $6.33. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.52 to $12.62 to $12.63 to $12.67. The company's 2021 adjusted diluted EPS guidance excludes $6.34 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Abbvie (ABBV) PT Raised to $273 at Canaccord
• Health Canada approves AbbVie's Boey for frown line treatment
• Qualcomm investor day to detail data center plans Wednesday